No insider purchase over the last 90 days. The latest was filed 10 Jul 2026.
EDGC belongs to the Health Care sector. Filings by its managers are published through DART (FSS). From 18 October 2025 to 18 October 2026, the disclosure feed for EDGC logged 11 filings by 6 insiders.
On the market, 3 insiders bought (5 purchases totalling €9.5M) while 3 insiders sold (6 sales). The amount is not disclosed for 9 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 major shareholder. 이롬 filed the largest purchase, €6.3M, on 8 May 2026.
Across the 2,648 companies tracked on its exchange, the median is 7 filings; at 11 filings, this issuer sits above that mark. The full history, which starts in 2021, counts 5 purchases against 14 sales.
Within a 30-day window, 2 purchases overlapped with buying by a second insider. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The latest purchase dates back some time: it was published 100 days ago, on 10 July 2026. The median gap between a trade and its publication by DART (FSS) is 22 days. That lag is the time during which only the insider knows about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
· cache
25 of 69 declarations
EDGC is a company operating in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions in the field of medical diagnostics and treatments.
Purchases our model currently ranks for the recommendations list.
All recommendations